Floatz logo

Cixutumumab

Recurrent Childhood Soft Tissue Sarcoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Recurrent Childhood Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Eloxatin
OHSU Knight Cancer Institute
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Cyteir Therapeutics, Inc.
Phase 2BB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2B
PREDNISONE TABLETS
Children's Oncology Group
Phase 2B

View all 9 →

Same molecule, other indications

Cixutumumab is also rated in:

Stage IV Breast Cancer AJCC v6 and v7Dormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →